• Protease Inhibitor Cocktail in Lysosome Research

  2026-09-24

  Learn how a Protease Inhibitor Cocktail EDTA-Free can preserve lysosomal proteins during sample preparation without confusing protein stability with organelle repair. This article connects recent findings on TECPR1-mediated lysosomal membrane tubulation to practical choices for extraction, phosphorylation analysis, and downstream assays.

• Batimastat (BB-94): MMP Assay & Model Workflows

  2026-09-24

  Use Batimastat (BB-94) to probe broad-spectrum MMP activity in enzyme assays, matrix-remodeling studies, and preclinical tumor models. This workflow also outlines a cautious way to test extracellular MMP involvement in localized BDNF processing—without confusing that hypothesis with the reference study’s demonstrated furin-dependent findings.

• Anti Reverse Cap Analog (ARCA): Evidence & Use

  2026-09-23

  Anti Reverse Cap Analog is a Cap 0 in vitro transcription cap analog designed to favor correct-orientation incorporation into synthetic mRNA. Product information reports approximately twofold higher translation efficiency than conventional m7G cap analogs, while the cited oligodendrocyte study supports synthetic mRNA reprogramming—not a direct test of ARCA.

• Primidone, RIPK1, and ALS Biomarker Translation

  2026-09-23

  The reference study links elevated peripheral RIPK1 and IL-8 with amyotrophic lateral sclerosis and evaluates Primidone as a pharmacological tool for suppressing this disease-associated signal. Its combined SOD1G93A mouse and human cohort design provides a translational framework for connecting RIPK1 inhibition with motor outcomes and blood-based biomarker monitoring.

• Aprotinin in Protease-Controlled GRO-seq Workflows

  2026-09-22

  Aprotinin adds targeted serine-protease control to extraction workflows while the reference GRO-seq strategy improves sequencing efficiency through rRNA depletion. This article connects practical BPTI handling with nuclear RNA profiling, cardiovascular blood-management research, and troubleshooting decisions that protect assay interpretability.

• Aprotinin (BPTI) for Cell Assays

  2026-09-22

  A practical, scenario-based guide to using Aprotinin (Bovine Pancreatic Trypsin Inhibitor, BPTI), SKU A2574, when protease activity may compromise cell viability, proliferation, or cytotoxicity assays. It connects mechanism, formulation, controls, data interpretation, and vendor-selection decisions to cited biochemical and biophysical evidence.

• GPNMB Model Predicts ESCC Immunotherapy Response

  2026-09-21

  This study identifies circulating soluble GPNMB as a mechanistically informative biomarker of resistance to PD-1 blockade in esophageal squamous cell carcinoma. By integrating plasma GPNMB, CAF-Epi niche features, and clinicopathological variables, the authors developed and validated a multimodal model with potential value for precision immunotherapy stratification.

• GS967: Cardiac Late Sodium Current Inhibitor

  2026-09-21

  GS967 supports a complete cardiac electrophysiology workflow, from concentration-controlled ventricular myocyte recordings to isolated-heart arrhythmia models. Its value is greatest when late sodium current inhibition is paired with measurements of repolarization, calcium handling, relaxation, and conduction.

• Coronavirus Macrodomains and PARP-Mediated Antiviral Defense

  2026-09-20

  Grunewald and colleagues showed that coronavirus macrodomains counter a PARP-dependent host response that restricts viral replication and promotes interferon production. The study combines pharmacologic inhibition, PARP12 and PARP14 knockdown, primary-cell infection, and mouse experiments to connect viral macrodomain activity with innate immune regulation.

• Pulmonary Arterial Remodeling and RV Afterload

  2026-09-19

  This study uses a subject-specific one-dimensional fluid–structure interaction model to separate how distal resistance and proximal arterial stiffness shape pulmonary hypertension hemodynamics. Its main finding is that increased distal resistance most strongly raises maximum main pulmonary artery pressure, whereas reduced compliance markedly increases characteristic impedance, providing a quantitative basis for more targeted interpretation of right ventricular afterload.

• Vidarabine Monohydrate in Cell Assays

  2026-09-18

  Learn how Vidarabine monohydrate, SKU C6377, can support more interpretable antiviral, proliferation, viability, and cytotoxicity workflows. This scenario-based guide focuses on solubility control, vehicle matching, assay design, data interpretation, and practical product selection.

• Aprotinin for RBC Membrane and Protease Assays

  2026-09-18

  Aprotinin connects reversible serine protease inhibition with practical workflows for red blood cell membrane mechanics, fibrinolysis studies, and cardiovascular surgery blood-management research. This guide translates multiscale membrane findings into controlled assay designs, dosing screens, and troubleshooting decisions without overstating clinical or mechanistic evidence.

• (-)-Arctigenin Workflows for NF-κB and MEK1 Studies

  2026-09-17

  Use (-)-Arctigenin as a pharmacological probe to connect inflammatory signaling, macrophage–tumor communication, and MEK1 biology in reproducible bench workflows. Its DMSO compatibility and nanomolar activity support dose-response experiments, while careful controls help distinguish NF-κB pathway modulation from nonspecific cytotoxicity.

• Phillygenin in Diabetic Nephropathy: Mechanistic Evidence

  2026-09-17

  The reference study shows that phillygenin protects against diabetic kidney injury by suppressing TLR4/MyD88/NF-κB-mediated inflammation and restoring PI3K/AKT/GSK3β-associated survival signaling. Its integrated podocyte, transcriptomic, biochemical, and db/db mouse data provide a preclinical framework for evaluating phillygenin as a candidate intervention in diabetic nephropathy.

• Thymoquinone Protects Against Doxorubicin Cardiotoxicity

  2026-09-16

  A 2025 mouse study reports that thymoquinone attenuates doxorubicin-induced cardiac injury while improving antioxidant defenses and mitochondrial morphology. Its findings connect Nrf2/HO-1 signaling with reduced ferroptosis-related damage, offering a mechanistic framework for refining cardiotoxicity models without yet establishing clinical or antitumor efficacy.

8752 records 1/584 page Next 12345 下5页 Last page